Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Neoplasms
Interventions: DRUG: Pembrolizumab|DRUG: IRX 2
Sponsor: Providence Health & Services
Collaborators: Merck Sharp & Dohme LLC|Brooklyn ImmunoTherapeutics, LLC